Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

NZ Delphic Signs Mega Deal With Japanese Giant

A major distribution agreement that will see NZ software used in hospitals and laboratories around the world was announced today.

New Zealand owned and operated software and e-commerce systems developer/exporter Delphic Medical Systems has recently signed a distribution agreement with Japanese medical giant, Sysmex. The agreement will guarantee New Zealand company Delphic, which produces highly innovative “across the net” medical laboratory software, total access to the US and European markets, piggybacking on the international Sysmex name.

“This is a huge coup for a New Zealand company,” says Mark Cox , Business Development Manager of Delphic Medical Systems. “Our export market was steadily growing but this agreement with Sysmex puts it on a global fast track.”

Sysmex is a public company, listed on the Tokyo Stock Exchange, with a turnover of US$340 million per annum. Sysmex Corporation, and its operating companies, such as Sysmex InfoSystems America, Sysmex Europe and Sysmex UK are a leading global manufacturer and marketer of diagnostic instrument and information systems which automatically test blood and urine for disease. Leadership positions include laboratory Hematology robotic Systems, where Sysmex has captured 95% of the global market share.

Announcing the agreement, President of Sysmex Mr Hisashi Ietsugu said: “This is in line with our strategy to establish a firm reputation in medical software. Delphic is a small but highly innovative company, which has demonstrated its ability to create leading edge technology. We are very pleased to have this association with them.”

Sysmex has offices in the UK, USA, France, Belgium and Germany, all highly profitable export markets with great potential for Delphic’s software products.

“Delphic are expecting massive growth in sales of “Delphic AP” and “Éclair” - now that Sysmex have opened the door to Europe and the US. Sysmex predicts that sales of the two products will grow to US$6 million within three years. This will mean increasing our employee numbers in New Zealand. It will also secure the global positioning of our company, already regarded as a leader in innovative software development for this sector,” says Mr Cox.

Delphic is a private company currently employing 42 people. It has already sold its Delphic AP (Anatomical Pathology) and Eclair software systems throughout New Zealand, and to sites in Australia, Singapore, USA and Holland.

Delphic AP, installed in community laboratories and in hospitals, is based on the latest version of Lotus Notes. It is part of a suite of software that provides an entirely electronic environment for reporting pathology results to referring doctors. The software interfaces with laboratory equipment, and generates reports about patients’ conditions for doctors.

The Eclair software suite is a first step hospitals can take to electronic medical records. It interfaces with Delphic AP – and other software systems – and is literally an “Electronic Clinical Information Repository” (Eclair)”. It is used for radiology and pathology reporting. Eclair allows patients’ results to be available on computer for doctors who need them, without generating paper. It permits hospitals to see lab results the moment they are done, rather than hours or days after ordering. Eclair is designed to be used on an intranet, and can also deliver results remotely across the Worldwide Web.

Although Delphic Medical Systems has been very successful in exporting its systems and in introducing them to other countries, the company found it needed to have a sales presence constantly in the US and Europe to really succeed.

“Through this deal, Delphic will grow in importance internationally. To give an idea of scale: in New Zealand there are 40 to 50 medical laboratories. In the USA there are 92,000 and around the same number in Europe,” says Mr Cox. “We needed to increase our scale to be competitive. We couldn’t achieve that easily without a distributor. Sysmex was the ideal partner. Their global growth strategy was a perfect fit with Delphic’s worldwide product vision.”

Mr Cox says Sysmex was attracted to Delphic because of the quality of its software, and its history of innovation.

“Our people have a unique mix of laboratory and IT backgrounds. As a result, our systems are robust, intuitive and developed with a good understanding of what the customer needs. Delphic is able to interact well with top quality medical institutions in New Zealand. This provides us and Sysmex with a strong environment for developing global software to a high standard. We can trial and test our products, and continue to develop them alongside the very professionals who use them,” he says.

“We’re currently supplying software in many other languages, and we have the advantage that New Zealand is an excellent, cohesive market in which to innovate new product adaptations.”

Delphic Medical Systems Limited is based in Auckland. It was founded 14 years ago by software pioneers James Webster and Roger Seaton, both of whom continue to create software for the company.

A key aim of the company is to create software that allows integration of information and records between primary, secondary and tertiary healthcare – or doctors, clinics and hospitals – at the click of a mouse. Delphic is also known for its New Zealand developed product WHOOSH, an on-line management system for safety and health systems. WHOOSH is also being developed offshore to help users in other countries manage their work safety and health needs.


Ends


For more information, Please contact: Mark Cox Phone (09) 630 3554
Mobile – 021 647 251
Released on behalf of Delphic by PRaxis Public Relations Limited: Catherine Peters Phone (09) 373-5068; mobile (025) 748-273
www.Delphic.co.nz

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Voluntary Administration: Renaissance Brewing Up For Sale

Renaissance Brewing, the first local company to raise capital through equity crowdfunding, is up for sale after cash flow woes and product management issues led to the appointment of voluntary administrators. More>>

Elsewhere:

Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:

Media Mega Merger: Full Steam Ahead For Appeal

New Zealand's two largest news publishers have confirmed they are committed to pursuing their appeal against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>